Integrating patient preferences with health utilities: A variation on health-related quality of life

Archives of Dermatology

Volumn 144, Issue 8, 2008, Pages 1037-1041

  VanBeek, Marta J ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISABILITY; EDITORIAL; HEALTH CARE UTILIZATION; PATIENT CARE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; SOCIAL ASPECT;

ACNE VULGARIS; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; HUMANS; PATIENT SATISFACTION; PSYCHOMETRICS; QUALITY OF LIFE; RISK; SICKNESS IMPACT PROFILE; SKIN DISEASES; SOCIAL VALUES;

EID: 49949083780     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.8.1037     Document Type: Editorial

References (40)

1. Chen CL, Kuppermann M, Caughey A, Zane LT. A community-based study of acne-related health preferences in adolescents. Arch Dermatol. 2008;144(8):989-995.
2. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis. 1987;40(6):593-600.
3. Andresen EM, Meyers AR. Health-related quality of life outcomes measures. Arch Phys Med Rehabil. 2000;81(12)(suppl 2):S30-S45.
4. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA. 1994;272(8):619-626.
5. Carr AJ, Higginson IJ. Measuring quality of life: are quality of life measures patient centered? BMJ. 2001;322(7298):1357-1361.
6. Constitution of World Health Organization. Chronicle of World Health Organization. Vol. 1. Geneva, Switzerland: World Health Organization; 1947:29-43.
7. Guyatt GH, Feeny DH, Patrick DL. Measuring health related quality of life. Ann Intern Med. 1993;118(8):622-629.
8. Guyatt GH, Cook DJ. Health status, quality of life and the individual. JAMA. 1994;272(8):630-631.
9. Garratt A, Schmidt L, Mackintosh A, et al. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ. 2002;324(7351):1417-1422.
10. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. JAMA. 1995;273(1):59-65.
11. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care. 1989;5(4):559-575.
12. Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;(5):707-713.
13. Chren MM, Lasek RJ, Quinn LM, et al. Convergent and discriminant validity of a generic and a disease-specific instrument to measure quality of life in patients with skin disease. J Invest Dermatol. 1997;108(1):103-107.
14. Chren MM, Lasek RJ, Flocke S, et al. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433-1440.
15. Finlay AY. Measure of the effect of adult severe atopic eczema on quality of life. J Eur Acad Dermatol Venereol. 1996;7(2):149-154.
16. Finlay AY. Quality of life measurement in dermatology: a practical guide. Br J Dermatol. 1997;136(3):305-314.
17. Finlay AY, Coles EC. The effect of psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132(2):236-244.
18. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol. 1999;140(4):672-676.
19. Hawthorne G, Osborne RH, Elliott P. Commentary on: a psychometric analysis of the measurement level of the rating scale, time trade-off and standard gamble, by Cook et al. Soc Sci Med. 2003;56(4):895-897.
20. Gold M, Siegel J, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
21. Kaplan RM, Anderson JP. The general health policy model: an integrated approach. In: Spilder B, ed. Quality of Life and Pharmaoeconomics in Clinical Trials. New York, NY: Raven Press; 1996:309-322.
22. von Neumann J, Morgenstern O. Theory of Games and Economics Behavior. Princeton, NJ: Princeton University Press; 1944.
23. Weinstein MC, Stasson WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296(13):716-721.
24. Torrance GW. Measurement of health state utilities for economic appraisal: a review. J Health Econ. 1986;5(1):1-30.
25. Ryan M, Scott DA, Reeves C, et al. Eliciting public preferences for healthcare: a systematic review of techniques. Health Technol Assess. 2001;5(5):1-186.
26. Jansen ST, Stiggelbout AM, Nooij MA, Kievit J. The effect of individually assessed preference weights on the relationship between holistic utilities and nonpreference-based assessment. Qual Life Res. 2000;9(5):541-557.
27. Patrick D, Erickson P. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation. New York, NY: Oxford University Press; 1992.
28. Read JL, Quinn RJ, Berwick DM, Fineberg HV, Weinstein MC. Preferences for health outcomes: comparisons of assessment methods. Med Decis Making. 1984;4(3):315-329.
29. Schiffner R, Brunnberg S, Hohenleutner U, Stolz W, Landthaler M. Willingness to pay and time trade-off: useful utility indicators for the assessment of quality of life and patient satisfaction in patients with port wine stains. Br J Dermatol. 2002;146(3):440-447.
30. Insinga RP, Fryback DG. Understanding differences between self-ratings and population ratings for health in the EuroQOL. Qual Life Res. 2003;12(6):611-619.
31. Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems: Health Utilities Index. Pharmacoeconomics. 1995;7(6):490-502.
32. US Valuation of the EuroQol EQ-5D Health States, December 2005. Agency for Healthcare Research and Quality Web site. http://www.ahrq.gov/rice/EQ5Dproj. htm. Accessed January 9, 2008.
33. Burström K, Johannesson M, Diderichsen F. A comparison of individual and social time trade-off values for health states in the general population. Health Policy. 2006;76(3):359-370.
34. McNeil BJ, Weichselbaum R, Pauker SG. Fallacy of the five-year survival in lung cancer. N Engl J Med. 1978;299(25):1397-1401.
35. Huguet N, Kaplan MS, Feeny D. Socioeconomic status and health-related quality of life among elderly people: results from the Joint Canada/United States Survey of Health. Soc Sci Med. 2008;66(4):803-810.
36. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol. 1999;141(6):1067-1075.
37. Fortune DG, Main CJ, O'Sullivan TM, et al. Assessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress Inventory. J Psychosom Res. 1997;42(5):467-475.
38. Hermansen SE, Helland CA, Finlay AY. Patients' and doctors' assessment of skin disease handicap. Clin Exp Dermatol. 2002;27(3):249-250.
39. Frost MH, Bonomi AE, Estwing CE. Patient, clinician and population perspectives on determining clinical significance of quality of life scores. Mayo Clin Proc. 2002;77(5):488-494.
40. Powles J, Day N. Interpreting the global burden of disease. Lancet. 2002;360(9343):1342-1343.